Bernstein launches coverage of Canada’s Tilray, Cronos and Canopy Growth but stops short of any buy ratings

Analyst Nadine Sarwat sees Cronos and Tilray as 'fairly valued' and Canopy Growth as 'meaningfully overvalued.'
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.